Manchester, UK, June 6th, 2019 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy (PT) solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the launch of myQA iON at the 2019 PTCOG conference.
myQA iON significantly reduces the time needed for patient QA: The use of PT machine log files, process automation, task-based workflows, and the latest web technologies significantly increase QA efficiency while ensuring patient treatment safety. Compared to conventional detector measurements (at isocenter), myQA iON enables a reduction of the QA measurement effort that results in a three times faster patient QA. This efficiency increase was confirmed by a global survey conducted amongst 37 practicing medical physicists at proton therapy centers.
“Combining irradiation logs and an independent dose recalculation with myQA iON, we intend to reduce the amount of measurements performed for patient QA by approximately 90%.”said Stefan Both, Professor & Head of Medical Physics at the Department of Radiation Oncology, University Medical Center Groningen, Netherlands.
myQA iON combines the analysis of irradiation log files and sophisticated high-accuracy Monte Carlo dose recalculation to provide the user with an independent QA dose calculation as well as the ability to verify the quality and safety of each patient treatment fraction.
“The ability to automate our patient QA, and the flexibility to use irradiation log files, real dose measurements, and Monte Carlo secondary recalculations in one system will bring us to a new level in PT treatment plan QA efficiency and accuracy,” said Zuofeng Li, PhysicsDirector at the University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA.
The software environment offers all patient QA tasks and workflow steps in a single interface. The latest web technologies allow users to access their patient QA anytime and anywhere within the hospital network. myQA iON supports patient QA for proton therapy machines of all major vendors.
“We are proud about our worldwide collaboration network with proton therapy centers. Customer feedback has always been our driver to develop integrated quality assurance solutions that help healthcare teams as well as the patients. As a result, the new myQA iON environment is an essential step to ensure proton therapy patient safety, and significant time savings needed for patient QA,” said Jean-Marc Bothy, President of IBA Dosimetry GmbH. “With myQA iON we offer a real game changer in proton therapy patient QA, allowing customers to increase patient throughput whilst increasing patient treatment quality.”
myQA iON is currently undergoing FDA 510(k) review.
To find out more please visit iba-dosimetry.com
About IBA Dosimetry
IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.
Find more information at iba-dosimetry.com
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at iba-worldwide.com
Director Global Marketing
IBA Dosimetry, email@example.com